

Please append the attached abstract to the application after the claims and number the page accordingly. The abstract is supported by the original abstract shown on the face of published PCT/FR97/01412. No new matter has been added.



IN THE CLAIMS:

Please amend claim 1 as follows:

1. (Twice Amended) Pharmaceutical composition intended for the treatment or prevention of a papillomavirus infection or tumor, which comprises, as therapeutic agents:

(1) at least one polypeptide from the early region of a human papillomavirus and at least one polypeptide from the late region of a human papillomavirus,

(2) at least one polypeptide from the early region of a papillomavirus and at least one polypeptide from the late region of a papillomavirus and at least one polypeptide having immunostimulatory activity, or

(3) at least one polypeptide from the early region or late region of a papillomavirus and at least one polypeptide having immunostimulatory activity.

wherein said polypeptide from the early region of a papillomavirus is not fused to the polypeptide from the late region of a papillomavirus.

Kindly add the following new claims:

--32. A pharmaceutical composition according to claim 1, wherein said composition comprises:

- (a) a polypeptide from the E6 region of a human papillomavirus;
- (b) a polypeptide from the E7 region of a human papillomavirus; and
- (c) interleukin 2;

wherein said polypeptide from the E6 region and said polypeptide from the E7 region are nononcogenic variants of the E6 and E7 proteins of said papillomavirus.

E4
cont

33. A pharmaceutical composition according to claim 1, wherein said composition comprises:

- (a) a polypeptide from the E6 region of a human papillomavirus;
- (b) a polypeptide from the E7 region of a human papillomavirus;
- (c) a polypeptide from the L1 region of a human papillomavirus;
- (d) a polypeptide from the L2 region of a human papillomavirus; and
- (e) interleukin 2;

wherein said polypeptide from the E6 region and said polypeptide from the E7 region are nononcogenic variants of the E6 and E7 proteins of said papillomavirus.--

REMARKS

This amendment is responsive to the Office Action dated August 4, 1998. Entry of the foregoing and favorable reconsideration of the subject application in light of the following remarks, pursuant to and consistent with 37 CFR §1.112, are respectfully requested.